Edgewise Therapeutics, Inc. announced the promotion of Behrad Derakhshan, Ph.D., to Chief Operating Officer, effective January 8, 2025. Dr. Derakhshan has served as the company’s Chief Business Officer since September 2020 and has an extensive background in biotechnology, including leadership roles at VectivBio, Therachon, and Alexion Pharmaceuticals. He also has experience in business development and strategic evaluation, with prior management consulting experience and a strong academic foundation, including a Ph.D. in Biochemistry.

In connection with his promotion, Dr. Derakhshan’s annual base salary increased from $478,400 to $520,000, and his target annual bonus rose from 40% to 45% of his salary for fiscal year 2025. There are no family relationships or arrangements tied to his appointment.

This promotion reflects Edgewise Therapeutics’ commitment to strengthening its leadership team as the company continues to advance its mission in the biotechnology sector.